News

Richmond medical technology company raises $1M

Richmond medical technology company Tympanogen Inc. has raised $1 million in fresh funding, according to a Securities and Exchange Commission filing.

Tympanogen raised the money from 12 investors and said it is seeking to raise up to $2.5 million through debt and other options, according to the March filing. The round includes participation from Williamsburg’s ShockVentures and Virginia Venture Partners, according to PitchBook.

The Richmond company also received funding in March from the NOLA Angel Network of New Orleans, according to NOLA.com. Tympanogen was founded in 2014 by Elaine Horn-Ranney and Parastoo Khoshakhlagh when they were pursuing their doctorates from Tulane University, which is located in New Orleans. The company set up shop in Virginia when Horn-Ranney and her husband moved to the state.

We’ve reached out to Horn-Ranney, who is the CEO, for comment and will update this story when we hear back. Companies generally do not comment on ongoing funding raises because of SEC regulations.

Tympanogen develops treatments to improve ear, nose and throat procedures, including a gel-patch system for eardrum repair called Perf-Fix.

Its lab space is located at Richmond’s VA Bio+Tech Park and the company counts seven employees on its website.

Tympanogen has racked up some previous grant funding, including $737,369 in November from Virginia Catalyst, a state life sciences organization funded by the general budget and state research universities. It also received $75,000 from the Commonwealth Research Commercialization Fund in 2020 and an undisclosed investment from the state’s Center for Innovative Technology in 2019. Crunchbase pegs the company’s lifetime funding at $2.3 million.

Recent News

07/01/2025

ISOThrive Announces Promising Phase 2 Interim Data for Novel Heartburn Treatment and Appoints Pharma Veteran Mike Walther as Chief Strategy Officer

ISOThrive Inc., a clinical-stage biopharmaceutical company, announced interim results from a Phase 2 study of its lead candidate, ISOT-101, for treatment of Non-Erosive Reflux Disease (NERD). The data showed positive trends in addressing heartburn frequency and symptom severity among proton pump inhibitor (PPI) partial-responders (PR), a patient population with major unmet medical need. These positive

07/01/2025

Gary Lowenthal Joins Focused Ultrasound Foundation’s Council

The Focused Ultrasound Foundation is pleased to welcome Gary Lowenthal to its Council, a dedicated group of goodwill ambassadors who work closely with the Board of Directors and staff to provide advice and assist with raising funds and building awareness. Mr. Lowenthal is a retired educator, entrepreneur, and executive with a career spanning education, international service,

06/25/2025

Liquet Medical Closes Oversubscribed Seed Round to Launch Pilot Study Evaluating Real-Time Hemodynamic Monitoring

Liquet Medical, a clinical-stage medical device company developing the Versus™ Catheter — a first-of-its-kind dual-tipped catheter system cleared by the FDA for controlled and selective infusion of fluids into the pulmonary vasculature and hemodynamic monitoring — announced the successful and oversubscribed close of its Seed funding round, which officially closed in May 2025. The capital